GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
13 Novembro 2023 - 10:00AM
Business Wire
- GSK launches Mapping Myelofibrosis to help chart course for
those affected by the disease.
- Myelofibrosis is a complex blood cancer that impacts nearly
25,000 people in the U.S.
GSK plc (LSE/NYSE: GSK) has partnered with former Queer Eye star
and interior designer Thom Filicia to launch Mapping
Myelofibrosis, a new health education initiative aiming to help
those impacted by myelofibrosis (MF) better navigate the disease.
This year marks the 10-year anniversary of Filicia donating bone
marrow to his brother, who was diagnosed with MF a few months prior
to the transplant. Filicia now looks to use his voice to help raise
awareness of this blood cancer, which can be difficult to diagnose
and manage.1
MF impacts nearly 25,000 people in the U.S. and is part of a
larger group of blood cancers that affect the bone marrow, called
myeloproliferative neoplasms (MPNs).2,3 Each person experiences MF
differently, presenting significant challenges in identifying
symptoms and mapping out treatment paths.1
“After my brother’s diagnosis, we didn't understand the
magnitude of what he was up against,” said Filicia. “The reality of
MF presents unique challenges for each individual, and as my
brother overcame this disease, I realized the need to ensure more
accessible information and resources. This experience led me to
team up with GSK on Mapping Myelofibrosis to continue raising
awareness of this complex blood cancer.”
Mapping Myelofibrosis includes the launch of a website featuring
educational resources about MF, community stories, and messages
from Filicia. In developing the initiative, GSK sought input from
the MF community through collaborations with organizations
including the MPN Research Foundation (MPNRF) and MPN Advocacy
& Education International (MPN A&E).
Faris El Refaie, Head of Oncology, U.S. of GSK said: “At
GSK, we are committed to advancing the standard of care in oncology
and supporting communities impacted by hematologic cancers.
Recognizing an unmet need in myelofibrosis, we developed Mapping
Myelofibrosis to cultivate awareness and provide a platform to
foster support and education.”
Kapila Viges, CEO of MPN Research Foundation said: “This
initiative by GSK represents a meaningful step forward in ensuring
those living with MF and their families have access to tailored
resources to help guide them through the complexities of this
disease. Hearing Filicia tell his story reinforces the importance
of enhancing our understanding of MF, and all MPNs.”
Ann Brazeau, CEO and Founder of MPN A&E said:
“Ensuring that patients with MF and their loved ones feel seen and
heard while navigating a rare disease is so important. Educational
resources like GSK’s Mapping Myelofibrosis initiative are critical
for patients and their families when it comes to making informed
decisions around their care.”
In early stages, approximately one third of individuals with MF
will not exhibit symptoms.1 However, key signs and symptoms of the
disease may include, but are not limited to low blood counts
(anemia), low platelet counts (thrombocytopenia) or enlarged spleen
(splenomegaly).1 For those who have not been diagnosed, early
detection of the disease may be beneficial. For those who have been
diagnosed, understanding your symptoms is key to making informed
decisions regarding treatment and care with your healthcare
providers.1
Explore MappingMF.com to find resources and learn more.
About Mapping Myelofibrosis GSK created Mapping
Myelofibrosis to increase awareness of myelofibrosis, seeking
to connect the community with educational tools, resources and
stories to help navigate all aspects of the disease.
Explore MappingMF.com to find resources and learn more about
myelofibrosis. You can also follow the initiative on Facebook.
About myelofibrosis (MF) Myelofibrosis is a complex blood
cancer affecting approximately 25,000 people in the U.S.2 MF is
part of a larger group of blood cancers that affect the blood and
bone marrow, known as myeloproliferative neoplasms, or MPNs.3 In
people with MF, blood cells may not be produced in a typical way,
causing inflammation and scarring of the bone marrow, which is
called fibrosis.3 The signs and symptoms of MF may include severe
low blood counts or anemia, enlarged spleen (splenomegaly), low
blood platelets (thrombocytopenia), and other symptoms.1
GSK in oncology GSK is focused on maximizing patient
survival through transformational medicines. GSK’s pipeline is
focused on immuno-oncology, tumor cell targeting therapies and
synthetic lethality. Our goal is to achieve a sustainable flow of
new treatments based on a diversified portfolio of investigational
medicines utilizing modalities such as small molecules, antibodies
and antibody-drug conjugates, either alone or in combination.
About GSK GSK is a global biopharma company with a
purpose to unite science, technology, and talent to get ahead of
disease together. Find out more at gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors” in the company's Annual Report on Form 20-F for
2022, and Q2 Results for 2023 and any impacts of the COVID-19
pandemic.
Registered in England & Wales: No. 3888792
Registered Office: 980 Great West Road Brentford,
Middlesex TW8 9GS
References:
- Cleveland Clinic. Myelofibrosis. Available at:
https://my.clevelandclinic.org/health/diseases/15672-myelofibrosis.
Accessed October 2023
- Data on file. Sierra Oncology. 2021.
- MPN Research Foundation. Primary Myelofibrosis (PMF). Available
at:
http://www.mpnresearchfoundation.org/primary-myelofibrosis-pmf/.
Accessed October 2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231110216675/en/
GSK inquiries Media: Kathleen Quinn +1 202 603 5003
(Washington DC)
Lyndsay Meyer +1 202 302 4595 (Washington DC)
Alison Hunt +1 540 742 3391 (Washington DC)
Investor Relations: Frannie DeFranco +1 215 751 4855
(Philadelphia)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024